Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Intra-Cellular Therapies, Inc. (ITCI) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"INTRA-CELLULAR THERAPIES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND RAISES 2023 CAPLYTA SALES GUIDANCE"
05/04/2023 8-K Quarterly results
03/28/2023 8-K Quarterly results
03/01/2023 8-K Quarterly results
01/09/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
12/22/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
11/03/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/25/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® for Specific Patient Populations"
04/21/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors NEW YORK, April 21, 2022 — Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, today announced the appointment of E. Rene Salas to the Intra-Cellular Therapies Board of Directors. Mr. Salas will serve as a member of the audit committee. “We are pleased to welcome Rene Salas to the Intra-Cellular Therapies Board,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “Rene's extensive financial and life sciences advisory experience will be very valuable as we continue to grow our business and pursue our mission to develop innovative treatments to improve the lives of patients.” Abo..."
03/01/2022 8-K Quarterly results
01/07/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares NEW YORK, January 7, 2022 — Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, today announced the completion of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share. In addition, the underwriters have exercised in full their option to purchase an additional 1,428,571 shares. All of the shares in the offering were sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies of approximately $460.0 million and net proceeds..."
01/05/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, by and among the Company, J.P. Morgan Securities LLC, SVB Leerink LLC, BofA Securities, Inc., Evercore Group L.L.C. and RBC Capital Markets, LLC, as representatives of the several underwriters named therein",
"Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C",
"Information relating to Item 14 of the Registration Statement on Form S-3 (File No. 333-235817)",
"Intra-Cellular Therapies Prices Public Offering of Common Stock NEW YORK, January 4, 2022 — Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, today announced the pricing of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $400.0 million before deducting underwriting discounts and commissions and offering expenses. Intra-Cellular Therapies has granted the underwriters a 30-day option to purchase up to an additional 1,428,571 shares on the same terms a..."
01/05/2022 8-K Financial Statements and Exhibits  Interactive Data
Docs: "Supply Agreement by and between Siegfried Evionnaz SA and ITI Limited",
"Supply Agreement by and between Siegfried Evionnaz SA and ITI Limited"
12/29/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment to Supply Agreement by and between Siegfried Evionnaz SA and ITI Limited",
"Amendment to Supply Agreement by and between Siegfried Evionnaz SA and ITI Limited"
12/20/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA ® for the Treatment of Bipolar Depression in Adults"
12/08/2021 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "INTRA-CELLULAR THERAPIES REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
08/09/2021 8-K Quarterly results
06/22/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
05/03/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
02/22/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "INTRA-CELLULAR THERAPIES REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
10/01/2020 8-K Quarterly results
09/11/2020 8-K Quarterly results
09/10/2020 8-K Quarterly results
09/09/2020 8-K Quarterly results
09/09/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Intra-Cellular Therapies Announces Positive Topline Results from Study 402 Evaluating Lumateperone as Adjunctive Therapy in Patients with Bipolar Depression"
08/10/2020 8-K Quarterly results
06/29/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy